PanGIA Biotech Debuts AI-Powered Urine Test for Early Prostate Cancer Detection at ASCO 2025

CHICAGO -- (BUSINESS WIRE) -- PanGIA Biotech, a pioneer in non-invasive cancer diagnostics, presented groundbreaking findings at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) from a large-scale, multi-center validation study. The research, titled "Development and Validation of an AI-Enabled Prediction of Prostate Cancer (PCa) Using Urine-Based Liquid Biopsy" (Abstract #3080), marks the first clinical validation of PanGIA's innovative method, which combines advanced chemistry with artificial intelligence (AI) to identify cancer-specific biosignatures from a simple urine sample. "This study reaffirms our belief in the potential of non-invasive, data-driven diagnostics," said Holly Magliochetti, CEO of PanGIA Biotech. "Our platform enables early detection of prostate cancer, allowing for timely intervention, without the need for expensive or invasive procedures." The key findings of the study highlighted several advantages of PanGIA's approach: Enhanced Accuracy in Early Detection: Unlike traditional invasive biopsies or blood-based tests, which can miss early-stage prostate cancer, PanGIA's method uses AI models to analyze urinary biosignatures. This eliminates the necessity for DNA sequencing, making the test more cost-effective and scalable. Global Scalability: The platform is designed to function across various healthcare settings, offering significant potential for widespread adoption around the world. This versatility is crucial for improving access to early cancer detection in resource-limited regions. Non-Invasive Nature: The urine-based test provides a comfortable and accessible alternative to more invasive methods, reducing patient anxiety and improving overall compliance with screening protocols. PanGIA Biotech has previously demonstrated the effectiveness of its platform through a study published in The Analyst, a journal of the Royal Society of Chemistry. This research detailed how the company's "Colorimetric Chemical Tongue" technology can detect and differentiate multiple analytes, underscoring the robustness of its diagnostic approach. About PanGIA Biotech PanGIA Biotech is dedicated to developing AI-integrated, urine-based liquid biopsy solutions that are designed for global scalability. The PanGIA® platform supports early detection, monitoring, and disease management of cancers, including those in Stage 1. By leveraging machine learning algorithms, the platform can interpret complex biomolecular patterns to provide precise diagnostic insights. Supported by a strong foundation of patents and peer-reviewed research, PanGIA Biotech aims to revolutionize healthcare through continuous innovation. For more information, visit www.PanGIABiotech.com. ¹ Lim FB, et al. “A Colorimetric Chemical Tongue Detects And Distinguishes Between Multiple Analytes.” The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J